Clinical Trials Directory

Trials / Conditions / Endometrial Mixed Cell Adenocarcinoma

Endometrial Mixed Cell Adenocarcinoma

10 registered clinical trials studyying Endometrial Mixed Cell Adenocarcinoma — 3 currently recruiting.

StatusTrialSponsorPhase
WithdrawnPET/MRI in Endometrial Cancer
NCT05390021
Massachusetts General HospitalN/A
RecruitingONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT05542407
UNC Lineberger Comprehensive Cancer CenterPhase 1
RecruitingTesting the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Se
NCT05256225
National Cancer Institute (NCI)Phase 3
RecruitingTesting Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial
NCT05112601
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTesting the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel a
NCT03914612
National Cancer Institute (NCI)Phase 3
Active Not RecruitingTesting the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and C
NCT03660826
National Cancer Institute (NCI)Phase 2
CompletedCopanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT02728258
NRG OncologyPhase 2
CompletedNab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance
NCT02020707
Mayo ClinicPhase 1
CompletedTrametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01935973
National Cancer Institute (NCI)Phase 1
CompletedCabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
NCT01935934
National Cancer Institute (NCI)Phase 2